Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Melanocyte development and malignant melanoma.

C R Goding1

  • 1Eukaryotic Transcription Laboratory, Marie Curie Research Institute, Surrey, UK.

Forum (Genoa, Italy)
|September 29, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells.

Oncogene·2016
Same author

Commentary. A picture of Mitf in melanoma immortality.

Oncogene·2011
Same author

Ectopic Tbx2 expression results in polyploidy and cisplatin resistance.

Oncogene·2007
Same author

Viral mutations enhance the Max binding properties of the vMyc b-HLH-LZ domain.

Nucleic acids research·2005
Same author

The melanocyte inducing factor MITF is stably expressed in cell lines from human clear cell sarcoma.

British journal of cancer·2003
Same author

The Usf-1 transcription factor is a novel target for the stress-responsive p38 kinase and mediates UV-induced Tyrosinase expression.

The EMBO journal·2001

Malignant melanoma, an aggressive skin cancer, shares developmental pathways with melanocytes. Key signaling pathways like receptor tyrosine kinases and Wnt are deregulated, impacting microphthalmia-associated transcription factor.

Area of Science:

  • Oncology
  • Dermatology
  • Molecular Biology

Background:

  • Malignant melanoma is an aggressive skin cancer with rising incidence.
  • Metastatic melanoma is often unresponsive to current therapies.
  • Unlike other cancers, common mutations (p53, retinoblastoma, Ras) are rare in melanoma.

Purpose of the Study:

  • To review molecular pathways deregulated in malignant melanoma.
  • To explore the link between melanoma and melanocyte development.
  • To highlight the role of specific signaling pathways and transcription factors.

Main Methods:

  • Review of scientific literature on melanoma molecular biology.
  • Analysis of signaling pathways involved in melanocyte development.
  • Focus on receptor tyrosine kinases, Wnt signaling, and p16INK4a.

Related Experiment Videos

Main Results:

  • Melanoma shares characteristics with melanocyte precursors.
  • Deregulation of receptor tyrosine kinases, Wnt pathway, and p16INK4a are implicated.
  • These pathways converge on the microphthalmia-associated transcription factor.

Conclusions:

  • Understanding melanocyte development pathways is crucial for melanoma research.
  • Targeting these deregulated pathways may offer new therapeutic strategies.
  • The microphthalmia-associated transcription factor is a key player in melanoma pathogenesis.